

Hepatitis C vaccine

A next-generation hepatitis C vaccine that combines viral vector technologies and optimized antigen design to induce broad, functional T cell responses across diverse HCV genotypes. The antigen is designed as a recombinant polypeptide and can be delivered through peptide, nucleic acid, or viral-vector formats, supporting broad-spectrum prophylactic and therapeutic vaccination strategies.

Applications: Vaccines, Hepatitis C



Features	Benefits
Pan-genotypic antigen design targeting HCV genotypes 1-6	Addresses challenges posed by viral genetic diversity
Conserved-region immunogen engineering	Expands immune recognition across diverse HCV strains
Suitable for viral vector or nucleic acid deliver approaches	Flexible vaccine development pathways
Induces broad CD4+ and CD8+ T cell responses	Enhances T cell cross-reactivity between genotypes and durable cellular immunity

Patented and Available for

- Co-development
- Consulting
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.